Choroidal Nevus Transformation Into Melanoma

Analysis of 2514 Consecutive Cases

Carol L. Shields, MD; Minoru Furuta, MD; Edwina L. Berman, BS; Jonathan D. Zahler, MD; Daniel M. Hoberman, BS; Diep H. Dinh, BS; Arman Mashayekhi, MD; Jerry A. Shields, MD

Arch Ophthalmology. 2009;127(8):981-987
<table>
<thead>
<tr>
<th>Mnemonic Initial</th>
<th>Hazard Ratio, Rounded/Actual (95% Confidence Interval)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No Features</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Feature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>2.2/1.1 (1.50-2.97)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>F</td>
<td>3/3.24 (1.61-6.53)</td>
<td>.001</td>
</tr>
<tr>
<td>S1</td>
<td>2/1.65 (1.07-2.54)</td>
<td>.02</td>
</tr>
<tr>
<td>S2</td>
<td>2/2.29 (1.34-3.91)</td>
<td>.002</td>
</tr>
<tr>
<td>O</td>
<td>3/3.77 (1.90-4.05)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>M</td>
<td>2/2.80 (1.25-2.59)</td>
<td>.001</td>
</tr>
<tr>
<td>U</td>
<td>3/3.87 (2.03-4.07)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>H</td>
<td>7/6.57 (1.62-26.69)</td>
<td>.009</td>
</tr>
<tr>
<td><strong>2 Features</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TF</td>
<td>5/4.66 (2.05-10.59)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TS1</td>
<td>2/2.17 (1.27-3.71)</td>
<td>.005</td>
</tr>
<tr>
<td>TS2</td>
<td>3/3.20 (1.39-6.05)</td>
<td>.005</td>
</tr>
<tr>
<td>TO</td>
<td>3/3.87 (1.81-4.56)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TM</td>
<td>2/1.81 (1.19-2.73)</td>
<td>.005</td>
</tr>
<tr>
<td>TU</td>
<td>3/3.11 (2.22-4.36)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TH</td>
<td>2/2.26 (1.26-3.17)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS1</td>
<td>5/5.09 (2.43-10.66)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS2</td>
<td>3/3.09 (0.74-12.04)</td>
<td>.12</td>
</tr>
<tr>
<td>FO</td>
<td>7/7.18 (2.11-24.46)</td>
<td>.002</td>
</tr>
<tr>
<td>FM</td>
<td>4/3.77 (1.78-7.97)</td>
<td>.001</td>
</tr>
<tr>
<td>FU</td>
<td>4/4.14 (1.79-9.57)</td>
<td>.001</td>
</tr>
<tr>
<td>FH</td>
<td>3/3.18 (1.54-6.65)</td>
<td>.002</td>
</tr>
<tr>
<td>S1O</td>
<td>2/2.30 (1.32-3.99)</td>
<td>.003</td>
</tr>
<tr>
<td>S2O</td>
<td>7/7.24 (2.89-18.11)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S1M</td>
<td>2/2.04 (1.28-3.25)</td>
<td>.003</td>
</tr>
<tr>
<td>S2M</td>
<td>3/3.23 (1.60-6.52)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S1U</td>
<td>3/3.53 (1.59-4.01)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S2U</td>
<td>4/3.86 (1.98-7.53)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S1H</td>
<td>2/1.72 (1.11-2.64)</td>
<td>.01</td>
</tr>
<tr>
<td>S2H</td>
<td>3/3.50 (1.47-4.26)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>O1</td>
<td>4/3.55 (2.35-5.36)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>OU</td>
<td>3/3.35 (2.16-5.18)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>OH</td>
<td>3/3.10 (2.13-4.51)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>UH</td>
<td>3/3.16 (2.25-4.46)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mnemonic Initial</th>
<th>Hazard Ratio, Rounded/Actual (95% Confidence Interval)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3 Features</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFS1</td>
<td>8/8.34 (2.98-23.36)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2</td>
<td>5/4.61 (1.11-19.15)</td>
<td>.04</td>
</tr>
<tr>
<td>TF0</td>
<td>6/6.15 (1.45-26.01)</td>
<td>.01</td>
</tr>
<tr>
<td>TFM</td>
<td>4/4.11 (1.60-10.58)</td>
<td>.003</td>
</tr>
<tr>
<td>TFU</td>
<td>6/6.45 (2.52-16.51)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TH</td>
<td>4/4.13 (1.72-9.92)</td>
<td>.001</td>
</tr>
<tr>
<td>TS1O</td>
<td>2/2.12 (1.02-4.42)</td>
<td>.04</td>
</tr>
<tr>
<td>TFS20</td>
<td>23/22.75 (3.12-165.73)</td>
<td>.002</td>
</tr>
<tr>
<td>TFS1M</td>
<td>2/1.93 (1.05-3.55)</td>
<td>.04</td>
</tr>
<tr>
<td>TFS2M</td>
<td>2/2.43 (0.77-7.63)</td>
<td>.13</td>
</tr>
<tr>
<td>TFS1U</td>
<td>3/3.45 (1.96-6.12)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2U</td>
<td>6/5.86 (2.55-13.47)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS1H</td>
<td>2/2.06 (1.19-3.86)</td>
<td>.01</td>
</tr>
<tr>
<td>TFS2H</td>
<td>3/3.09 (1.48-6.45)</td>
<td>.003</td>
</tr>
<tr>
<td>TOM</td>
<td>3/3.31 (1.98-5.53)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TOH</td>
<td>3/3.19 (2.01-5.04)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TOU</td>
<td>4/4.42 (2.66-7.33)</td>
<td>.001</td>
</tr>
<tr>
<td>TMH</td>
<td>2/1.87 (1.23-2.83)</td>
<td>.003</td>
</tr>
<tr>
<td>TMU</td>
<td>3/3.20 (2.10-4.88)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TUF</td>
<td>3/3.28 (2.34-4.60)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS1O</td>
<td>9/9.38 (2.89-30.44)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS2O</td>
<td>7/7.48 (3.43-16.34)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Mnemonic</th>
<th>Hazard Ratio, a Rounded/Actual (95% Confidence Interval)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Features (continued)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FS1MU</td>
<td>8/8.34 (2.59-26.84)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS2MU</td>
<td>8/7.55 (1.84-31.09)</td>
<td>.005</td>
</tr>
<tr>
<td>FS1MH</td>
<td>7/6.79 (2.94-15.68)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FS2MH</td>
<td>5/5.26 (1.28-21.69)</td>
<td>.02</td>
</tr>
<tr>
<td>S1OMU</td>
<td>4/3.61 (1.91-6.83)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S2OMU</td>
<td>30/29.59 (7.21-121.53)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S1OMH</td>
<td>3/3.36 (1.95-5.80)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S2OMH</td>
<td>10/10.26 (3.70-28.44)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S1MUH</td>
<td>3/2.74 (1.65-4.55)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>S2MUH</td>
<td>6/6.04 (2.52-14.51)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>OMUH</td>
<td>5/5.00 (3.17-7.89)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>5 Features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFS1OM</td>
<td>15/14.95 (3.65-61.19)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2OM</td>
<td>11/10.89 (1.51-78.76)</td>
<td>.02</td>
</tr>
<tr>
<td>TFS1OU</td>
<td>10/9.91 (2.41-40.79)</td>
<td>.001</td>
</tr>
<tr>
<td>TFS2OU</td>
<td>8/7.58 (1.03-55.88)</td>
<td>.047</td>
</tr>
<tr>
<td>TFS1OH</td>
<td>8/7.45 (1.76-31.52)</td>
<td>.006</td>
</tr>
<tr>
<td>TFS2OH</td>
<td>5/4.97 (2.31-10.67)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS1OMU</td>
<td>6/5.97 (3.50-10.18)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2OMU</td>
<td>4/3.91 (2.07-7.39)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>6 Features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFS1OMU</td>
<td>20/19.63 (2.73-141.30)</td>
<td>.003</td>
</tr>
<tr>
<td>TFS2OMU</td>
<td>16/15.97 (3.90-65.36)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS1OMH</td>
<td>11/11.39 (1.58-82.37)</td>
<td>.02</td>
</tr>
<tr>
<td>TFS2OMH</td>
<td>6/5.74 (0.79-41.89)</td>
<td>.08</td>
</tr>
<tr>
<td>TFS1MUH</td>
<td>16/16.43 (4.04-66.86)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2MUH</td>
<td>8/7.69 (1.04-56.71)</td>
<td>.045</td>
</tr>
<tr>
<td>TFS1OMUH</td>
<td>5/5.22 (2.43-11.22)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>TFS2OMUH</td>
<td>10/9.96 (1.37-72.19)</td>
<td>.02</td>
</tr>
<tr>
<td>7 Features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFS1OMU</td>
<td>21/20.60 (2.86-148.27)</td>
<td>.003</td>
</tr>
</tbody>
</table>

Abbreviations: F, subretinal fluid (ophthalmoscopically visible); H, halo absence; M, margin within 3 mm of the disc; O, orange pigment; S1, symptom of decreased vision/visual field defect; S2, symptom of flashes/floaters; T, thickness greater than 2 mm; U, ultrasonographic hollowness.

a Compared with eye without feature using multivariable analysis. In the multivariate model, the combinations other than those specified are included as individual predictors. For example, to estimate the hazard ratio for the combination TF, the other factors, S, M, O, H, and U, are included as independent predictors in the model.

b This combination of risk factors did not occur.